Raloxifene can upregulate the expression of eNOS (NOS3) in rat thoracic aorta, and it is expected to exert a potentially important vasculo-protective effect, and to contribute to clinical improvements in ARDS and pulmonary hypertension [63], concept already tested in clinical trials also with other compounds [64]. Here, NOS3 is linked to pulmonary arterial hypertension.